Needham raised the firm’s price target on Celcuity (CELC) (CECL) to $95 from $70 and keeps a Buy rating on the shares. The firm considers updated results from the PIK3CA wild-type cohort of the pivotal VIKTORIA-1 study as further de-risking for geda and potentially practice changing. Furthermore, Needham thinks a lack of PFS benefit observed for Roche’s (RHHBY) oral SERD giredestrant in ESR1 WT patients removes an overhang on Celcuity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELC:
- Celcuity rises 47.7%
- Morning Movers: Cleveland-Cliffs surges following earnings report
- Celcuity provides update on status of PIK3CA mutant cohort
- Celcuity presents updated data at 2025 ESMO for Phase 1 study of gedatolisib
- Celcuity announces results from PIK3CA wild-type cohort of Phase 3 VIKTORIA-1